Abstract
The last decade has seen the increasing use of genetics and genomics tools in the pharmaceutical industry, and much of this use has been in the drug discovery process. These tools are now becoming part of the standard discovery armamentarium and are being used across a range of areas from novel target identification to early predictors of intersubject variability. As with many innovations in the drug discovery process, the true value of pharmacogenomics will take many years to determine, as the new range of molecularly targeted and assessed compounds go through development. The expectation is that the use of the techniques described in this chapter will reverse the current trend of high drug failure rates and hence ensure that the next wave of innovative medicines reaches the waiting patient population.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
7 References
Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov. 1(9):727–30
Silber BM (2000) Pharmacogenomics, biomarkers and the promise of personalised medicine. In: Sadée W (ed) Pharmacogenetics-Pharmacogenomics. American Association of Pharmaceutical Scientists.
Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–5
Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafri H, Mannan J, Raashid Y, Al-Gazali L, Hamamy H, Valente EM, Gorman S, Williams R, MchHale DP, Wood JN, Gribble FM, Woods CG (2006) An SCN9A channelopathy causes congenital inability to experience pain. Nature 444(7121):894–8
Samson M, Libert F, Doranz BJ et al (1996) Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382(6593):722–5.
Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, Pape J, Cheshier RC, Murphy PM (2006) CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 203(1):35–40
Wheeler J, McHale M, Jackson V, Penny M (2007) Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc. Antivir Ther 12(2):233–45.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Duncan, M. (2008). Applications of Pharmacogenomics in Drug Discovery. In: Cohen, N. (eds) Pharmacogenomics and Personalized Medicine. Methods in Pharmacology and Toxicology. Humana Press. https://doi.org/10.1007/978-1-59745-439-1_4
Download citation
DOI: https://doi.org/10.1007/978-1-59745-439-1_4
Publisher Name: Humana Press
Print ISBN: 978-1-934115-04-6
Online ISBN: 978-1-59745-439-1
eBook Packages: Springer Protocols